NCT05760248View on ClinicalTrials.gov

Safety and Efficacy Study of 10XB-101 in Adults With Bilateral Flank Adiposity

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

May 4, 2023

Primary Completion Date

January 22, 2025

Study Completion Date

January 22, 2025

Conditions
Subcutaneous Fat Disorder
Interventions
DRUG

10XB-101 Solution for Injection, 6.0%

The active drug (adipolytic) given as subcutaneous injection on either the right or left flank every 4 weeks for 20 weeks.

DRUG

Placebo Solution for Injection (no active ingredient)

Placebo given as subcutaneous injection on either the right or left flank every 4 weeks for 20 weeks.

Trial Locations (2)

55112

Site #02, New Brighton

60008

Site #01, Rolling Meadows

Sponsors

Lead Sponsor

10xBio, LLC
All Listed Sponsors
collaborator

Therapeutics, Inc.

INDUSTRY

lead

10xBio, LLC

INDUSTRY